Gracell Biotechnologies
A clinical-stage biotech company with mission to solve CAR-T industry hurdles.
Launch date
Employees
Market cap
$990m
Enterprise valuation
$769m (Public information from Feb 2024)
Share price
$10.25 GRCL
Shanghai Shanghai (HQ)
Financials
Estimates*
| CNY | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenues | - | - | <1m | - | - | - | - |
| EBITDA | (144m) | (207m) | (385m) | (593m) | (681m) | (813m) | (885m) |
| % EBITDA margin | - | - | (105226 %) | - | - | - | - |
| Profit | (139m) | (212m) | (452m) | (608m) | (500m) | (614m) | (719m) |
| % profit margin | - | - | (123430 %) | - | - | - | - |
| EV / revenue | - | - | 8101.3x | - | - | - | - |
| EV / EBITDA | - | - | -7.7x | -1.9x | -8.4x | -7.7x | -5.8x |
| R&D budget | 119m | 169m | 327m | 485m | - | - | - |
| R&D % of revenue | - | - | 89317 % | - | - | - | - |
| Date | Investors | Amount | Round |
|---|---|---|---|
N/A | Series A | ||
$85.0m | Series B | ||
$100m | Series C | ||
| N/A | N/A | IPO | |
* | $100m | Private Placement VC | |
* | $1.0b Valuation: $1.2b -14.7x EV/LTM EBITDA | Acquisition | |
| Total Funding | $285m | ||
Related Content
Recent News about Gracell Biotechnologies
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.